Loading
Colorectal and Anal Carcinomas / Cancer Research and Treatments · Journal article
Medicine · August 14, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a single case report of a patient with recurrent lung adenocarcinoma and subcutaneous and adrenal metastases treated with platinum-based chemotherapy and pembrolizumab, who achieved marked regression of metastatic lesions with minimal adverse events. The report is descriptive and hypothesis-generating only; it does not establish efficacy or safety through controlled evidence and cannot be generalised to guide practice.
Single-case report. One 60-year-old male with recurrent lung adenocarcinoma metastatic to subcutaneous soft tissues and adrenal gland, who had undergone prior surgical resection.. Intervention: Platinum-based doublet chemotherapy combined with pembrolizumab (PD-1 inhibitor) administered over several cycles as second-line systemic therapy.. n = 1.
Marked regression of metastatic lesions observed following several treatment cycles Minimal treatment-related adverse events reported Durable clinical response achieved in the single patient treated
Minimal treatment-related adverse events reported
This case report does not provide sufficient evidence to guide clinical decision-making. The authors themselves note that further clinical trials are warranted to validate the combination approach. Clinicians should weigh this anecdotal observation within existing evidence on PD-1 inhibitors and chemotherapy in advanced NSCLC.
A single case report with no comparator, control group, or quantified efficacy metrics; describes feasibility and tolerability rather than establishing efficacy through controlled evidence.
As stated by the source record.
This case report does not provide sufficient evidence to guide clinical decision-making. The authors themselves note that further clinical trials are warranted to validate the combination approach. Clinicians should weigh this anecdotal observation within existing evidence on PD-1 inhibitors and chemotherapy in advanced NSCLC.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Rationale: Despite available therapies, patients with advanced non-small cell lung cancer have a poor prognosis, highlighting the need for novel treatment strategies. The combination of immune checkpoint inhibitors and chemotherapy represents a promising approach. This case report describes the efficacy and safety of this combination in a patient with aggressive metastatic disease. Patient concerns: A 60-year-old male patient, who had undergone surgical resection for primary lung adenocarcinoma, presented with newly developed subcutaneous nodules and symptoms suggestive of adrenal involvement during routine follow-up. Diagnoses: Histopathological and imaging examinations confirmed recurrent lung adenocarcinoma with metastases to the subcutaneous soft tissues and the adrenal gland. Interventions: The patient received platinum-based doublet chemotherapy combined with pembrolizumab (an anti-programmed cell death protein 1inhibitor) as second-line systemic therapy. Outcomes: Following several treatment cycles, imaging revealed marked regression of metastatic lesions, with only minimal treatment-related adverse events reported. The patient achieved a durable clinical response. Lessons: This case suggests that combining chemotherapy with programmed cell death protein 1 inhibition may provide rapid and effective tumor control in advanced non-small cell lung cancer patients with bulky, symptomatic metastases, while maintaining a manageable safety profile. Further clinical trials are warranted to validate this approach.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.